NCT05744375 2026-03-12
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
Clinical Trials
17 trialsNCT06048718 2026-03-10
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT06486883 2026-03-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT05376878 2026-02-23
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
City of Hope Medical Center
Phase 4 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07428044 2026-02-23
HERCULES
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
NCT06250777 2026-02-09
ELPIS
Yonsei University
Phase 2 Enrolling by invitation
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT05633979 2026-01-20
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05408845 2026-01-14
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT07340164 2026-01-14
TROY
Yonsei University
Phase 2 Not yet recruiting
NCT07126561 2026-01-08
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
Phase 2 Not yet recruiting